Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
| 対象疾患 | Treatment Resistant Major Depressive Disorder |
|---|---|
| 相 | 第4相 |
| スポンサー | Massachusetts General Hospital |
| ステータス | 完了 |
| 参加者数 | 278 名 |
| 介入（薬剤） | Aripiprazole, Repetitive transcranial magnetic stimulation (rTMS), Venlafaxine XR |
| 開始日 | 2017年7月13日 |
| 完了日 | 2022年4月24日 |
| 結果公開日 | 2026年7月9日 |
概要
This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.
Montgomery-Asberg Depression Rating Scale (MADRS)
| Aripiprazole Augmentation | -14.9 ± 1.1 points |
|---|---|
| rTMS Augmentation | -17.39 ± 1.3 points |
| Switch to Venlafaxine XR/Duloxetine | -13.22 ± 1.1 points |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital